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Synthesis and metabolism of cysteinyl leukotrienes by the isolated pig
kidney. The metabolism and synthesis of cysteinyl leukotrienes by the
isolated perfused pig kidney has been investigated. Kidneys were
maintained for up to six hours in a recirculating perfusion system by
using an oxygenated Krebs-Henseleit buffer containing albumin and the
perfluorinated oxygen carrier, FC-43. Perfusion pressure was main-
tained at 12—13.5 kPa, with perfusion flow rates of 150—250 mllmin
resulting in a urine output of between 20—180 mi/hr. Infusion of
3H-LTC4 into the renal artery resulted in rapid and complete metabo-
lism, with the major urinary metabolites comprising LTE4, io-hydroxy-
LTE4, w-carboxy-LTE4 and N-acetyl-w-hydroxy-LTE4. The capacity
of the isolated kidney to synthesize cysteinyl leukotrienes was moni-
tored by measuring urinary LTE4 excretion; there was a basal urinary
excretion of LTE4 (median 43 pg/mm, range 8—470 pg/mm). Neither
lipopolysaccharide or human recombinant tumor necrosis factor alpha
had any effect on basal excretion. Treatment with the calcium iono-
phore A23 187, however, resulted in a 38.1 9.6-fold increase in urinary
LTE4 excretion. We conclude that the isolated pig kidney, in the
absence of circulating cells, can synthesize cysteinyl leukotrienes in the
absence of circulating cells, which can then undergo extensive oxida-
tive metabolism.
The cysteinyi leukotrienes (LTC4, D4 and E4) are potent
modulators of renal function, and when infused in vivo may
reduce both renal blood flow and glomerular filtration [1—3].
This effect may be due to their vasoconstrictor action and
stimulation of mesangial cell contraction [4, 5]. The leuko-
trienes have been implicated in the pathogenesis of a number of
renal disorders, including nephrotoxic serum nephritis in the
rat, murine lupus nephritis, and hepatorenal syndrome in hu-
mans [6—9]. It is unlikely that circulating leukotrienes have any
direct renal effects. LTC4 and LTD4 are rapidly metabolized in
blood to the weak spasmogen, LTE4, with the maximum
circulating levels of the LTE4 less than 7 pg/mi [8, 10]; even in
patients with hepatorenal syndrome, where substantial leuko-
tnene synthesis occurs, maximal plasma levels of LTE4 are still
too low to have a direct effect on the kidney [8]. In order for
leukotrienes to influence renal hemodynamics, synthesis must
occur within the kidney, and there is now evidence that the
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kidney has the capacity to generate leukotnenes. Assem and
Abduilah demonstrated increased LTC4 immunoreactivity fol-
lowing immunologic challenge in the isolated guinea pig kidney
[11], and more recently Merab and colleagues demonstrated
increased renal venous effluent levels of LTC4 and LTD4
following challenge with calcium ionophore (A23 187) in the
isolated rabbit kidney [12]. In this study we have demonstrated
that the isolated pig kidney can both synthesize and metabolize
cysteinyl leukotrienes in the absence of circulating cells.
Methods
Authentic standards of LTC4, D4 and E4 and their metabo-
lites were obtained from Cascade Biochem (University of
Reading, Berks, UK). Solvents for high performance liquid
chromatography (HPLC) were obtained from Rathburn (Pee-
bleshire, UK). Calcium ionophore (A23 187, Novabiochem,
Notts, UK) was prepared as a 10 m solution in dimethyl
suiphoxide. Lipopolysaccharide (LPS, E.Coli 055.B5) was ob-
tained from Sigma (Poole, UK) and human recombinant tumor
necrosis factor alpha (TNF) was a gift from Eurocetus, Am-
sterdam.
Isolated pig kidney model
Pigs (20—25 kg) were anesthetized with halothane, ketamine
and fentanyl. The left or right kidney was exposed, and the
renal artery cannulated with a clamp time of less than 90
seconds. The kidney was perfused in situ at 37°C at approxi-
mately 150 mllmin with oxygenated Gelofusine: Krebs-Hense-
leit buffer (4:1 vol/vol) until complete excision of the kidney and
clearing of red cells (less than 2 mm). The perfusate was then
changed to comprise Krebs-Henseleit buffer (2 parts) and FC 43
(a perfluorinated oxygen carrier, Merck UK) (1 part), contain-
ing a final concentration of bovine serum albumin (3.2%),
glucose (10 mM), and Synthamin 19 (1%). The final concentra-
tion of glucose takes into account the glucose present in the
Synthamin. The perfusate was continuously gassed (95% 02,
5% C02) using a pediatric hollow fiber oxygenator (Dideco,
Masterfiow). The kidney was removed and immediately placed
in an organ bath at 37°C, suspended in netting in the perfusate.
Perfusion pressure was monitored with a pressure transducer
and maintained at 12 to 13.5 kPa. Perfusion was continued for
up to five hours; the effluent from the renal vein was allowed to
pass directly back into the organ bath from where it passed into
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LTE4 0.18%; LTB4 <0.2%; arachidonic acid <0.1%. The
antibody used in the assay has a useable range from 5—160 pg,
with 50% binding at —30 pg. The antibody is available from
Cascade Biochem (Reading, Berks, UK).
Immunoaffinity columns
Fig. 1. Schematic of the isolated pig kidney perfusion system. The
kidney is immersed in an organ bath at 37°C and perfused through the
renal artery at approximately 150 to 200 ml/min with oxygenated
Krebs-Henseleit buffer containing bovine serum albumin, amino acids,
glucose and the perfluorinated oxygen carrier, FC43. Perfusion pres-
sure was monitored and maintained at 12 to 13.5 kPa.
the oxygenator and recirculated into the artery (Fig. 1). The
recirculating system had a total volume of 1 liter, and after
each urine collection, the volume was replaced with an equal
volume of Krebs-Henseleit buffer diluted 1:2 with water. Ap-
proximately 30 minutes were allowed for the kidney to equili-
brate, after which time basal urine collections were made for up
to one hour before pharmacological intervention (LPS, TNF, or
A23187) or infusion of radiolabelled LTC4. Drugs were infused
into the outflow tract of the organ bath leading to the oxygen-
ator and thence directly into the renal artery. These gave a final
concentration of approximately 10 ILM for calcium ionophore
A23 187 (0.1% DM50), 10 tg/ml for lipopolysaccharide and 10
ng!ml for TNF. Urine was collected at suitable intervals for
assay of LTE4 or identification of cysteinyl-leukotriene metab-
olites.
LTE4 antibody
Antibodies to LTE4 were prepared by immunization of New
Zealand White rabbits (pre-immunized with BCG) with a con-
jugate of LTE4-PPD (purified protein derivative, Ministry of
Agriculture, Food, and Fisheries, UK) synthesized using the
glutaraldehyde method, and in one rabbit resulted in a final
working titer of 1:64,000. The immunoglobulin fraction was
obtained by ammonium sulphate precipitation and dialysis
against buffer and water at 4°C. Any precipitate formed (mainly
lipoproteins) was discarded and the final solution diluted with a
one-third volume of 0.1 M phosphate buffer. An antiserum
dilution curve for the final solution was determined. Radioim-
munoassay (RIA) standard curves were generated using an
antiserum dilution sufficient to give 30 to 50% binding. All
assays were carried out in phosphate buffered saline with
charcoal phase separation. A final dilution of the purified
antiserum giving a 40% bind with a B/B0 of 80%, and 20% for
the S pg and 80 pg standards used in all subsequent assays. The
cross reactivity of the antibody was as follows: LTC4 16%;
LTD4 25%; LTE4 100%; 11-trans LTE4 32%; LTE4 sulphoxide
24%; N-acetyl LTE4 72%; w-hydroxy-LTE4 0.35%;
Immunoafflaity columns were prepared according to the
method of Chiabrando et al [13]. Briefly, 2.4 g cyanogen
bromide activated sepharose 4B (Pierce Warmer) was washed
in 500 ml hydrochloric acid (1 mM). Two ml of the immuno-
globulin fraction in 10 ml of sodium bicarbonate buffer (pH 8.3)
was shaken with activated sepharose for four hours at room
temperature. This was then washed with acetate buffer (pH
4.0), followed by borate buffer (pH 8.0) and the remaining
active groups inactivated with 6% ethanolamine. The slurry was
washed with acetone:water (9:1) and stored in 25 ml 0.1 M
phosphate buffer before pouring into 2 ml Analytichem columns
for use.
LTE4 extraction and assay
Renal production of cysteinyl-leukotrienes was assessed by
measuring urinary LTE4 excretion using HPLC-RIA. A known
volume of urine containing —8000 dpm [3H]-LTE4 (58 Ci!
mmole, Amersham International) as internal standard was
corrected to pH 7.4, centrifuged, and passed through an immu-
noaffinity column with an equal volume of phosphate buffer at
room temperature over 10 minutes. After loading, the column
was washed with 25 ml water. Elution was carried out by adding
0.75 ml acetonitrile:water (1:3) containing 0.6% concentrated
ammonia, left for 10 minutes, eluted with 0.75 ml acetone:water
(9:1), freeze dried, and resuspended in HPLC buffer. Samples
were then loaded for on-line extraction, and further purification
by HPLC in methanol:water on a Hypersil ODS column (Shan-
don Assoc.) using a flow rate of 2 ml/minute as previously
reported [8, 14]. The elution position of LTE4 was identified
from the radiolabeled internal standard and six 1 ml fractions
eluting around this time were collected for radioimmunoassay.
Immunoassay was carried out in duplicate using the antibody as
described above. The presence of LTE4 was accepted only
when LTE4 immunoreactivity coeluted with the 5H-LTE4 inter-
nal standard. In each sample, urinary LTE4 was determined
following correction for background immunoreactivity, and
also for recovery of the 3H-labelled internal standard. Back-
ground immunoreactivity using this method is low (around 2
pg/tube).
Metabolite analysis
A 10 ml bolus of 3H-LTC4 in saline (1—2 tCi) was infused as
above and urine collected at 15 minute intervals up to 90
minutes. Urine samples were extracted on-line and purified by
HPLC on a Hypersil ODS column using an extended methanol:
water HPLC gradient as described previously for LTE4 metab-
olite analysis [10]. Radioactivity in each fraction (0.75 ml) was
determined by scintillation counting in Optiphase safe (5 ml) on
a 2000CA liquid scintillation counter (Packard Technology).
Results
Renal synthesis and metabolism of the cysteinyl leukotrienes
has been investigated in an isolated pig kidney system (Fig. 1);
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a blood-free system was chosen to prevent non-renal leuko-
triene production or catabolism which is known to occur with
circulating cells. Sufficient oxygen delivery to the tissues was
achieved at a normal flow rate (150—200 ml/min) and perfusion
pressure (12—13.5 kPa) by the addition of the perfluorinated
oxygen carrier, FC43, to the perfusate. In the absence of FC43,
preliminary studies demonstrated that it was necessary to
increase flow rates to >500 ml/min to prevent tissue hypoxia,
and this was accompanied by an unacceptably high increase in
perfusion pressure. The isolated perfused pig kidney was stable
at 37°C for three to six hours and produced large volumes of
urine (20—180 ml/hr), which tended to increase with time.
Perfusion pressure was maintained at the above level, with a
gradual decrement in perfusion rate, indicating a progressive
increase in vascular resistance.
To determine the metabolic capacity of the kidney, [3H]-
LTC4 was infused into the renal artery in four separate prepa-
rations. Radioactivity was slowly excreted into urine, with 19 to
29% of the infused dose recovered within 90 minutes. Following
an initial screening using our standard HPLC system [141, it was
clear that extensive metabolism had occurred with little LTC4
or LTD4 found in urine. LTE4 was present together with a
number of polar and unresolved radiolabelled species. To
separate these metabolites, an extended HPLC gradient was
developed [10] and the elution times of authentic LTC4 metab-
olites were determined: LTC4 47 minutes; LTD4 63 minutes;
LTE4 57 minutes; LTE4 sulphoxide 52.5 minutes; N-acetyl-
LTE4 50 minutes; -hydroxy-LTE4 37.2 minutes; o-Carboxy-
LTE4 35.5 minutes; N-acetyl-w-hydroxy-LTE4 33.5 minutes;
N-acetyl-w-Carboxy-LTE4 32.5 minutes; w-dinor-LTE4 29.5
minutes; N-acetyl-dinor-LTE4 28 minutes; w-tetranor-dihydro-
LTE4 26 minutes; N-acetyl-o-tetranor-dihydro-LTE4 25 min-
utes. All metabolite analyses were carried out on this improved
HPLC system and the retention times of the radioactive metab-
olites compared with those of standards, run at the beginning
and end of every four samples. There was considerable varia-
tion of oxidative metabolism in each of the four kidneys
studied. co-hydroxy-LTE4 was a major urinary metabolite ex-
creted in three out of the four kidneys (representing 10.0%,
18.2%, and 26.0% of radiolabel excreted over 90 mm), com-
pared with LTE4 which accounted for 7.5%, 3.9%, and 10.6% of
total radioactivity in this time (Table 1). Other major metabo-
lites included w-carboxy-LTE4 (5.8—14.3%) and its dinor (3.6—
9.3%) and dihydro-tetranor metabolites (0—6.8%). Trace
amounts of LTE4 suiphoxide were also present. N-acetyl LTE4
was also generated, (0.2—0.9%) together with larger amounts of
its co-oxidation products, N-acetyl-w-hydroxy LTE4 (3.8—
13.2%) and N-acetyl-co-carboxy LTE4 (2.4—3 .2%). In the fourth
pig there was relatively little oxidative metabolism and LTE4
represented 50% of radioactivity excreted over 90 minutes, and
this was the only pig to demonstrate any, albeit minor amounts,
of radiolabeled LTC4 or LTD4 in the urine. Over the perfusion
period there was a gradual loss of LTE4 in all cases, and this
was accompanied by an increase in the proportion of polar
metabolites in the urine (Fig. 2).
The appearance of LTE4 in urine following infusion of LTC4
into the renal artery allows us to monitor renal production of
leukotrienes by immunoaffinity adsorption followed by HPLC-
RIA of LTE4. We chose LTE4 since a radiolabel of this
compound was readily available and enabled measurement by
Table 1. LTC4 metabolite profile in four isolated pig kidneys
Pig I Pig 2 Pig 3 Pig 4
LTC4 0.5 0 0.1 2.9
LTD4 0.2 0 0.1 2.3
LTE4 7.5 10.6 3.9 50.0
LTE4-sulphoxide 1.0 0 1.4 1.8
N-acetyl-LTE4 0.4 0.9 0.2 0.8
w-hydroxy-LTE4 10.0 26.0 18.2 4.2
w-carboxy-LTE4 14.3 13.0 5.8 2.1
N-acetyl-co-hydroxy-LTE4 13.2 3.8 6.5 1.2
N-acetyl-o-carboxy-LTE4 2.8 3.2 2.4 1.0
w-dinor-LTE4 9.3 3.6 7.6 1.3
w-tetranor-dihydro-LTE4 6.8 0 5.9 1.1
N-acetyl-&-dinor-LTE4 3.9 3.2 4.1 1.2
N-acetyl-u-tetranor- 3.1 0 5.4 0.8
dihydro-LTE4
Unaccounted radiolabela 27.0 35.7 38.5 29.3
Total 100 100 100 100
All values in the table represent the percentage of each metabolite
excreted over 90 minutes. The relative amount of each metabolite
varied depending on the time following administration, with a gradual
decrease in urinary LTE4 which was accompanied by an increase in the
amount of o-oxidation products (Fig. 1).
a Theunaccounted radioactivity constituted a generalized increase of
background counts which was not associated with any particular peak
radioimmunoassay. There was a basal urinary excretion of
LTE4, (median 43 pg/mm) and although there was a wide
difference between the kidney preparations (range 8—470 pg/
mm), this basal production was essentially constant for each
tissue (Fig. 3a). Urinary LTE4 was not affected by including
either lipopolysaccharide or TNF in the superfusate (Fig. 3b, c)
however, treatment with the calcium ionophore A23 187 caused
a marked increase (38.1 9.6 fold) in urinary LTE4 in 4/5
kidneys tested (Fig. 4), and this was accompanied by a transient
increase in perfusion pressure (of between 36 and 53 mm Fig).
One kidney did not respond to ionophore, and both urinary
LTE4 and perfusion pressure remained constant.
Discussion
There is now compelling evidence to implicate the cysteinyl
leukotrienes as causal agents in the pathogenesis of certain
forms of renal failure [1—3]. The circulating levels of the
leukotrienes are extremely low [8, 14], and only when produced
locally within the kidney are these substances likely to modify
renal function. The biological effects of the cysteinyl leuko-
trienes will be controlled not only by the rate of synthesis, but
also by the rate of metabolism and excretion. To investigate
these factors, we have developed an isolated perfused pig
kidney model and examined the synthesis and metabolism of
LTC4. The perfiuorinated oxygen carrier, FC43, was used to
improve oxygen delivery, and enabled perfusion at physiologi-
cal flow rates and pressure in the absence of circulating cells.
The pig kidney was chosen for study (instead of the more
readily available rat tissue) since porcine renal physiology and
systemic leukotriene metabolism more closely resemble those
in humans.
There is a basal production of the cysteinyl leukotrienes by
the kidney in the absence of circulating cells. lonophore chal-
lenge leads to a mean 38-fold increase in LTE4 excretion. It was
not clear why the single kidney did not respond to ionophore
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Fig. 3. Basal urinary excretion of LTE4 remains stable in the absence
of (A) is not altered by infusion of either tumor necrosis factor (TNF)
(B) or lipopolysaccharide (LPS) (C) into the renal artery.
bed [17]. There is evidence that the renal failure which accom-
panies endotoxemia can be ameliorated with leukotriene antag-
onists [18]. Many of the actions of endotoxins are mediated
through TNF, and it has been demonstrated that infusion of
TNF into rats [19] and humans [20] leads to an increase in
cysteinyl leukotriene production. Neither TNF nor lipopolysac-
charide had any stimulatory effect on leukotriene production by
the kidney. These data are not consistent with a direct effect of
these substances on renal leukotriene production in vivo,
although we cannot exclude synergism of these agents with
other cytokines or time-dependent effects through secondary
mediators.
The conversion of LTC4 through to LTE4 has been docu-
mented by others in both rat renal cells 1211 and large vessels in
the pig [221 and is catalyzed by y-glutamyl transferase and renal
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Fig. 4. Following stimulation with calcium ionophore A23187, there is
a marked increase in urinary LTE4 excretion by 4/5 isolated pig kidneys
(closed circles). No change in urinary LTE4 was observed in a single
kidney (open circles). Two kidneys had received either LPS or TNF
before ionophore challenge.
0
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Fig. 2. HPLC-radiochromatogram of urine (from pig 1) collected at
time 0 to 15 minutes (a), 30 to 45 minutes (b) and at 75 to 90 minutes (c)
following infusion of 3H-LTC4. There is a progressive decrease in the
proportion of LTE4 in urine with time formation of co-oxidized metab-
olites. The major metabolites are marked: (I) LTE4, (2) LTE4 sulphox-
ide, (3) N-acetyl-LTE4, (4) co-hydroxy-LTE4, (5) co-Carboxy-LTE4, (6)
N-acetyl-w-hydroxy-LTE4, (7) N-acetyl-w-Carboxy-LTE4, (8) co-dinor-
LTE4, (9) N-acetyl-dinor-LTE4: (10) w-tetranor-dihydro-LTE4: 26 min-
utes. LTC4 and LTD4 elute at 47 minutes and 63 minutes, respectively.
challenge, however, given that there are considerable differ-
ences in leukotriene metabolism between kidneys (Table 1), it is
possible that extensive and rapid metabolism of LTE4 has
occurred in this case. The cellular source of leukotriene syn-
thesis is not known although there is evidence for 5-lipoxygen-
ase activity within the glomerulus [15]. Other sources could
include tissue resident inflammatory cells [161 and the vascular
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dipeptidase. In our perfused kidney preparation, renal metabo-
lism of LTC4 was observed in all tissues with LTE4 appearing in
the urine. It is likely that LTE4 would also be the predominating
species in the perfusate, as indeed it is in the circulation in
humans [101. Although a proportion of LTE4 was cleared
unchanged, it was further converted to a number of metabo-
lites, with w-oxidation, presumably through the action of cy-
tochromes P450, as a major metabolic pathway in 3/4 kidneys.
The cellular site of this w-oxidation within the kidney is not
defined although it is known that the mammalian kidney pos-
sesses cytochromes P450 and is capable of catalyzing w and w-l
oxidations of fatty acids [23]. Only small amounts of N-acetyl
LTE4 were present in urine, although larger amounts of its
o-oxidation products, particularly N-acetyl-w-hydroxy LTE4
were detected. This may be due to kinetic reasons, with
N-acetylation followed by rapid w-oxidation or through a dif-
ferential effect of renal clearance on N-acetyl LTE4 and its
oxidative metabolites, In the fourth kidney, although perfusion
pressure and urine output were normal and there was no
evidence of hypoxia, a-oxidation was greatly reduced and the
major urinary metabolite was LTE4. As the enzyme activities of
y-glutamyl transferase and renal dipeptidase were unaffected,
there appears to have been some specific reduction of the
cytochrome P450 activity in this tissue. Metabolism by the pig
kidney is unlike that of the rat kidney, where the sole metabolite
of LTC4 is N-acetyl LTE4 [24]. The rat kidney is capable of
cytochrome P450-mediated oxidation [25] and these differences
may relate to a lack of a specific isozyme in the rat. Krebs-
Henseleit buffer has a poor oxygen carrying capacity, and it
may be that perfusion of the rat kidney with this buffer has
resulted in some hypoxia, and a consequent reduction in P450
activity.
In man, intravenous infusion of LTC4 also results in the
urinary excretion of LTE4 and its w-oxidized metabolites [10,
26]. It is not clear whether w-oxidation in man in vivo occurs in
the kidney or the liver, however, it is interesting to note that,
following infusion of 3H-LTC4 in humans, the proportion of
radiolabeled w-hydroxy-LTE4 found in urine [101 was much
lower than that produced in the isolated kidney preparation. It
is possible that measurements of urinary w-hydroxy-LTE4
(perhaps as a ratio with LTE4) may offer a mechanism by which
renal leukotriene production can be estimated.
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